The third accuracy study assessed the instrument’s performance in detecting small insertions and deletions by analyzing six samples using the Cystic Fibrosis 139 Variant Assay, which included a subset of clinically significant indels in CFTR. The detected insertions and deletions were all confirmed with bidirectional Sanger sequencing as the reference method. This evidence concerns the gene CFTR and cystic fibrosis.